FILING ANALYSIS · THURSDAY, NOVEMBER 12
ANAPTYSBIO, INC ANAB — 8-K: Results of Operations and Financial Condition
neutral
AnaptysBio reported strong Q1 financial results with $1.0 billion in Jemperli global net sales, representing 29% year-over-year growth, and announced a recent U.S. approval for Jemperli in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The company also provided updates on its litigation with GSK and Tesaro, and its collaboration with Vanda for Quimilza, with a judgment ant
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →